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In addition to standard management of PTL, women with amniotic fluid glucose levels <5 mg/dL and/or with microorganisms at Gram stain and/or positive cultures, were treated with antibiotics being tocolysis discontinued and magnesium sulfate administered <32 weeks if delivery was imminent. Induction of labor was only considered if clinical chorioamnionitis, gestational age >34 weeks and depending on the virulence of microorganism isolated.
An adverse neonatal outcome was defined by the occurrence of stillbirth/neonatal death or moderate/severe bronchopulmonary dysplasia or gastro-intestinal perforation or necrotizing enterocolitis or intra-ventricular haemhorrage grade III/IV or periventricular leukomalacia or early-onset sepsis or retinopathy of prematurity needing laser treatment.
We evaluated the independence of infection or IAI to explain an adverse neonatal outcome by logistic regression analysis. RESULTS: Two-hundred sixty-three women were included: 35(13%) with microbial-associated IAI (infection with IAI), 37(14%) with sterile IAI (IAI without infection), 12(5%) with microbial invasion of amniotic cavity (infection without IAI) and 179 (68%) women with non-infection/non-IAI.
We found significant differences on latency to delivery between women with or without infection or IAI. The presence of infection or IAI was associated with an adverse neonatal outcome mainly due to a high rate of stillbirth. However, when we selected from women who achieved 24 weeks (n 257) those who were managed with antenatal steroids and antibiotics (n 128), the significant influence of infection or IAI on neonatal outcome disappeared. CONCLUSION: In women with PTL, the information of infection or IAI may be useful to individualize our management targeting those women who are inevitably going to deliver in the following days and avoiding unnecessary overtreatments (e.g. transfer to NICU hospitals, need of antenatal steroids) in those with non-infection/non-IAI. OBJECTIVE: Extreme preterm birth (EPB), defined as birth at 28 weeks gestation, is a primary cause of infant mortality and an important health crisis. This study aims to quantify the impact of a variety of characteristics on EPB using attributable risk percentage (ARP). STUDY DESIGN: We performed a statewide population-based retrospective cohort study of all live births in Ohio from January 2006 through December 2015 . Births were stratified into 28 weeks gestation and >28 weeks gestation. Prevalence of sociodemographic, maternal, and fetal characteristics was compared between the two groups. Adjusted relative risk for EPB was estimated with multivariate logistic regression, and attributable risks were calculated. RESULTS: 17,615 of the 1,463,506 live births in Ohio from 2006-2015 (1.2%) were extremely preterm. Sociodemographic factors associated with EPB included lack of prenatal care, maternal education level, Black race, and smoking in the first or second trimester. Associated maternal comorbidities included overweight body mass index, diabetes, hypertension, gonorrhea, chlamydia, and hepatitis C. Associated fetal factors were cesarean delivery, male sex, and being large for gestational age. Risks identified were lack of prenatal care (ARP 70.6%, CI 68.4-72.6%), prior preterm birth (ARP 63.2%, CI 61.2-65.2%), smoking in the first two trimesters of pregnancy (ARP 61.6%, CI 58.9-64.1%), chronic hypertension (ARP 56.5%, CI 52.7-59.9%), Black race (ARP 56.0%, CI 54.2-57.6%), inadequate weight gain (ARP 45.3%, CI 43.2-47.4%), pregestational diabetes (ARP 36.3%, CI 26.6-44.7%), and preeclampsia (ARP 30.7%, CI 25.9-35.1%). CONCLUSION: EPBs differ from other births over a wide variety of sociodemographic, maternal, and fetal characteristics. Some risk factors are potentially modifiable and demonstrate the impact of interventions during pregnancy; for example, 210 EPBs in Ohio per year could be prevented if mothers gained the recommended amount of weight. The ARP values allow these findings to be applied to any target population. Our results provide a basis for appropriate allocation of resources in EPB prevention efforts. indicators of 17P response for recurrent SPTB prevention Tracy Manuck, Lisa Smeester, Rebecca C. Fry University of North Carolina, Chapel Hill, NC OBJECTIVE: We sought to quantify maternal plasma exosome-derived miRNAs known to target the nitric oxide (NO) pathway as surrogate biomarkers of cervical remodeling in women on 17P for recurrent PTB prevention. STUDY DESIGN: Prospective cohort of women with 1 prior SPTB receiving 17P in a subsequent singleton, non-anomalous gestation at a single tertiary institution. Maternal plasma was collected at 12-24 wks. Exosomes were separated from plasma by ultracentrifugation. We quantified the expression of 3 NO pathway-controlling miRNAs (miR-543, miR-940, miR-2143) using TaqMan assays. Women were classified as 17P non-responders (recurrent SPTB <34 wks) or 17P responders (delivery 37 wks), and miRNA expression compared. The secondary outcome was recurrent PTB <24 wks. A statistical cut point was calculated for each miR to determine the optimal sensitivity and specificity of the miR in SPTB prediction. Women were classified as having a 'high' or 'low' result for each miR based on this cut point. Data were analyzed using t-test, Fisher's exact, ANOVA, and Kaplan-Meier curves. RESULTS: 24 women with a prior SPTB on 17P were included; twelve 17P non-responders and twelve 17P responders. Maternal plasma was sampled at a median 15.9 (IQR 14.9-18.1) wks for 17P responders and 20.0 (IQR 18.2-22.3) wks for 17P non-responders, p¼0.024. 17P nonresponders delivered at a median 25.4 (IQR 22.2-30.4) wks; 5/12 delivered <24 wks. Absolute expression of each miR did not vary by 17P responder status. However, expression of miR-543 was increased in those with recurrent PTB <24 wks compared with women delivering at term (6.8 vs. 5.1, p¼0.009), and those with high miR-543 expression delivered earlier (median 25.1 vs. 34.0 wks, p¼0.013), Figure. There was also a trend towards earlier delivery with high expression of miR-2143 (median 24.0 vs. 37.3 wks, p¼0.053), Figure. Prediction models for 17P nonresponse combining miR-543 and miR-2143 expression and controlling for sample GA had an AUC of 0.83 (95% CI 0.66 e 1.0), PPVof 67%, and NPV of 67%. Prediction improved when considering only women delivering 24 wks (AUC 0.93, 95% CI 0.81-1.0, PPV 75%, NPV 85%). CONCLUSION: The expression of miR-543 derived from circulating plasma exosomes differentiates between 17P responders and nonresponders. miR-543 targets 29% of NO pathway genes. These studies should be validated using a larger sample size and further interrogate the role of the NO pathway and response to 17P.
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